Rapid Evolution: From Digitized To Agentified In Two Years

Approvals have held at roughly 50 new treatments a year since 2000, despite steady investment in R&D and technology. The argument here is that the bottleneck is less any single failure than the "operational whitespace" between systems, people, and decisions, and that generative and agentic AI are being applied to close it.

Expect an economic analysis from Tufts CSDD with commentary from Ken Getz and Dr. Pamela Tenaerts, results from deployments at a top-5 pharma company, and a look at the agents built for monitoring, oversight, TMF management, and consent.

Explore the evidence behind the 1-day startup, 1-day enrollment, and 1-year conduct vision.